文献速递骨软组织肉瘤与黑色素瘤

晚期皮肤癌影像学不明病灶的CT引导活检:47例回顾性分析

Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases.
PubMed 文献 · Eur J Cancer · 2021-04-23

该单中心回顾性研究纳入2010至2018年接受CT引导活检(CTGB)的晚期皮肤癌患者,其中47例用于 clarify 影像学可疑但性质不明的病灶。在未接受系统治疗(队列A)和正在接受系统治疗(队列B)的患者中,CTGB均证实约四成为皮肤癌转移,约四成为良性炎症/纤维化/感染,另有部分为其他恶性肿瘤。接受BRAF/MEK抑制剂者中CTGB证实转移比例高并导致治疗改变,而免疫检查点抑制剂治疗者中仅少数证实转移、多数为良性改变。

要点

  • CTGB可区分皮肤癌转移、良性改变及其他恶性肿瘤。
  • BRAF/MEK抑制剂治疗中CTGB常证实转移并影响治疗决策。
  • 免疫检查点抑制剂治疗中CTGB多显示良性炎症或纤维化。

核心结论

  • 在启动或更换抗肿瘤治疗前,CTGB有助于排除良性病变和第二原发恶性肿瘤。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2018年接受CTGB的晚期皮肤癌患者,其中47例用于 clarify 影像学可疑不明病灶。

主要发现

  • 队列A(未接受系统治疗,n=32)中CTGB证实皮肤癌转移占37.5%,良性炎症/纤维化/感染占37.5%,其他恶性肿瘤占25.0%。
  • 队列B(CTGB时接受系统治疗,n=15)中皮肤癌转移占40.0%,良性改变占46.7%,其他恶性肿瘤占13.3%。
  • 接受BRAF/MEK抑制剂的患者中,CTGB证实可疑病灶为皮肤癌转移的比例为83.3%,并导致治疗改变。
  • 接受免疫检查点抑制剂的患者中,仅11.1%证实皮肤癌转移,77.8%为良性组织改变(炎症/纤维化)。

临床怎么用

  • 对影像学性质不明的病灶,可考虑CTGB以明确诊断并指导治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiological imaging such as computed tomography (CT) is used frequently for disease staging and therapy monitoring in advanced skin cancer patients. Detected lesions of unclear dignity are a common challenge for treating physicians. The aim of this study was to assess the frequency and outcome of CT-guided biopsy (CTGB) of radiologically unclear, suspicious lesions and to depict its usefulness in different clinical settings. METHODS: This retrospective monocentric study included advanced skin cancer patients (melanoma, Merkel cell carcinoma, squamous cell carcinoma, angiosarcoma, cutaneous lymphoma) with radiologically unclear lesions who underwent CTGB between 2010 and 2018. RESULTS: Of 59 skin cancer patients who received CTGB, 47 received CTGB to clarify radiologically suspicious lesions of unclear dignity. 32 patients had no systemic therapy (cohort A), while 15 patients received systemic treatment at CTGB (cohort B). In both cohorts, CTGB revealed skin cancer metastasis in a large proportion of patients (37.5%, 40.0%, respectively), but benign tissue showing inflammation, fibrosis or infection in an equally large percentage (37.5%, 46.7%, respectively). Additionally, a significant number of other cancer entities was found (25.0%, 13.3%, respectively). In patients receiving BRAF/MEK inhibitors, CTGB confirmed suspicious lesions as skin cancer metastasis in 83.3%, leading to treatment change. In immune checkpoint inhibitor-treated patients, skin cancer metastasis was confirmed in 11.1% of patients only, whereas benign tissue changes (inflammation/fibrosis) were found in 77.8%. CONCLUSIONS: Our results highlight the relevance of clarifying radiologically unclear lesions by CTGB before start or change of an anti-tumour therapy to exclude benign alterations and secondary malignancies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Franklin C, Wetter A, Baba HA, et al. Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. Eur J Cancer. 2021. PMID: 33895683. doi:10.1016/j.ejca.2021.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。